JPMorgan making positive comments on major pharma stocks
- Firm expects anouther round of guidance updates in the light of the continued strengthening of the dollar
- Firm remains focused on new product launches, which firm sees driving upside to Street estimates- Reiterates Overweight on BMY, MRK, and PFE
- Reiterates Neutral on LLY, and ZTS